ZYUS Life Sciences’ (ZYU) “Buy” Rating Reiterated at Roth Capital

Roth Capital reissued their buy rating on shares of ZYUS Life Sciences (CVE:ZYUFree Report) in a research note issued to investors on Thursday, PriceTargets.com reports.

Separately, Stifel Canada restated a speculative buy rating on shares of ZYUS Life Sciences in a research note on Friday, January 26th.

Check Out Our Latest Report on ZYU

ZYUS Life Sciences Price Performance

Read More

Receive News & Ratings for ZYUS Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZYUS Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.